Mycophenolate Therapy and Associated Fetal Risk: Improving Healthcare Providers Competence in Pregnancy Planning and Contrac
Tracking # 20-1315083
Free
There are no ratings for this course
Learn moreCourse overview
The goal of this educational activity is to provide physicians, nurses, and pharmacists with education covering the Mycophenolate REMS program requirements, including increased risks of miscarriage and birth defects associated with MPA use during pregnancy, the need to counsel women of reproductive potential on the importance of pregnancy prevention and planning when taking MPA, and the need to report pregnancies to the Mycophenolate Pregnancy Registry.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Pharmacy
Pharmacist
Disclosure statements
Dr. Gabardi has disclosed that he has received grant/research support from Shionogi Pharmaceuticals; and consultant/advisory board fees from Merck and Takeda in the past 24 months.
Dr. Crespo-Bosque has disclosed that she has served as a clinical trial principal investigator for Biogen.
The clinical reviewer, Lisa Holle, PharmD, BCOP, FHOPA, has disclosed that she has no relevant affiliations or financial relationships with a commercial interest to disclose.
Susanne E. Batesko, MSHF, BSN, RN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
The PIM planners and others have nothing to disclose.
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.